Vision2Voice

Biopharma Healthcare Communications in a Post COVID-19 World. What’s Next?

Watch this candid and timely discussion with Biopharma and Healthcare industry professionals about the current state of peer-to-peer healthcare communications, overcoming challenges, and what the future may hold.

WEBINAR
Program Length 60 minutes


Moderator:
Daniel Rehal, Vision2Voice Healthcare Communications
Special Guests:
David Kendall, MD, MannKind Corporation
Jason Riley, Horizon Therapeutics

Vision2Voice Virtual Online Meetings

Enter Your Information To View this Webinar

Your Contact Information Is Secure And Will Never Be Shared, Rented Or Sold.

Most Biopharma professionals are facing an uncertain future for delivering mission critical communications and moving programs forward due to disruptions caused by the pandemic.

We'll look at the current state of industry communications and ponder the real-world tactics needed for future progress through the perspective of industry experts who face the same challenges that you do.

Who Should View? Biopharma industry professionals who had healthcare programs planned that were disrupted or delayed by COVID-19 complications.

Your Host

Daniel J. Rehal, President, Vision2Voice

Dan founded Vision2Voice Healthcare Communications in 2008 to continue his passion of connecting healthcare professionals to the resources that improve patient care.

Dan understands the pharmaceutical industry from the ground up. He has his BS and MBA from the University of Iowa spending his time studying pharmacy, chemistry, and business. He ascended the ranks at Merck early in his career and eventually assumed global responsibilities at Takeda. Dan has decades of experience in both marketing and sales roles supporting a multitude of pharmaceutical brands as an award-winning Sales Representative, Training Manager,Sales Leader,Sr. Product Manager, and Commercial Leader.

Special Guests

David Kendall MD, Chief Medical Officer, MannKind Corporation

With over two decades of healthcare experience, David Kendall has seen the industry from many perspectives, including pharmaceutical, association side and academic. Currently, he is a Chief Medical Officer of MannKind Corporation and has previously served as Vice President, Global Medical Affairs for Eli Lilly Diabetes, Associate Professor of Clinical Medicine at the University of Minnesota, and Chief Scientific and Medical Officer of the American Diabetes Association.

Jason Riley, General Manager & Vice President Rare Disease Business Unit, Horizon Therapeutics

Jason Riley has over 18 years of pharmaceutical industry experience and has spent the last five years at Horizon Therapeutics overseeing metabolic diseases and the Rare Disease Business Unit. Previously, Jason was the Associate Director of Epilepsy Marketing at Lundbeck and Product Manager of Diabetes, Cardiovascular Marketing at Takeda.